Advertisement
Hosting the call will be Feng Lan, Director and President, and QionghuaGao, Chief Financial Officer.
To participate in the event by telephone, please dial (800) 291-9234 fiveto 10 minutes prior to the start time (to allow time for registration) andreference the conference ID 46154547. International callers should dial (617)614-3923 and reference the same passcode.
Advertisement
A digital replay of the call will be available on Friday, November 16 atapproximately 10:00 a.m. EST through Friday, November 23 at 12 p.m. EST. Tolisten to the replay, dial (888) 286-8010 and enter the conference ID number98064518. International callers should dial (617) 801-6888 and enter the sameconference ID number.
The conference call will also be webcast live over the Internet and can beaccessed by all interested parties at the company's Web site,http://www.shenghuo.com.cn .
To monitor the live webcast, please visit the Company's Web site and clickon the webcast link at least 15 minutes prior to the start of the call toregister, download, and install any necessary audio software. An audio replayof the event will be archived on China Shenghuo's Web site, athttp://www.shenghuo.com.cn .
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("ChinaShenghuo" or "the "Company") is a specialty pharmaceutical company thatfocuses on the research, development, production and marketing of Sanchi-basedmedicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical(Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Foodand Drug Association)-approved medicines, including the flagship productXuesaitong Soft Capsules, which has already been listed in the InsuranceCatalogue. At present, China Shenghuo incorporates a sales network of agenciesand representatives throughout China, which markets Sanchi-based traditionalChinese medicine to hospitals and drug stores as prescription and OTC drugsprimarily for the treatment of cardiovascular, cerebrovascular and pepticulcer disease. The Company also exports medicinal products to Asian countriessuch as Indonesia, Russia and Kyrgyzstan. For more information, please visithttp://www.shenghuo.com.cn .
Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: This press release contains certain "forward-looking statements," asdefined in the United States Private Securities Litigation Reform Act of 1995,that involve a number of risks and uncertainties. There can be no assurancethat such statements will prove to be accurate and the actual results andfuture events could differ materially from management's current expectations.Such factors include, but are not limited to, the company's reliance on onesupplier for Sanchi, ability to develop and market new products, ability toestablish and maintain a strong brand, continued maintenance of certificates,permits and licenses required to conduct business in China, protection ofcompany's intellectual property rights, market acceptance of the company'sproducts, changes in the laws of the People's Republic of China that affectthe company's operations, the company's ability to obtain all necessarygovernment certifications and/or licenses to open and operate retail specialtycounters to offer its cosmetic products and conduct the company's business,cost of complying with current
